一例接受艾曲泊帕治疗的免疫性血小板减少性紫癜患者并发心房颤动的疑难病例：抗凝困境
A Challenging Case of a Patient With Immune Thrombocytopenic Purpura on Eltrombopag Who Developed Atrial Fibrillation: An Anticoagulation Dilemma.
作者信息
Yasin Ahmed K, Abu-Tineh Mohammad, Alshurafa Awni, Ahmed Khalid, Abdulgayoom Mohammed, Afana Mohammad, Yassin Mohamed A
机构信息
Department of Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Department of Medical Oncology, Hematology and Bone Marrow Transplant Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QAT.
出版信息
Cureus. 2023 Feb 15;15(2):e35001. doi: 10.7759/cureus.35001. eCollection 2023 Feb.
A 61-year-old female, who was a known case of immune thrombocytopenic purpura (ITP) on eltrombopag, was admitted for atrial fibrillation (AF). Labs showed a platelet count of 116 × 10/µL. AF reverted to sinus rhythm by cardioversion. Therapeutic enoxaparin was started for two days. She was discharged on dabigatran for four weeks. The choice of anticoagulation in these cases (ITP and AF) is not straightforward and needs further research.
一名61岁女性，已知患有免疫性血小板减少性紫癜（ITP），正在服用艾曲泊帕，因心房颤动（AF）入院。实验室检查显示血小板计数为116×10/µL。通过心脏复律，房颤恢复为窦性心律。开始使用治疗剂量的依诺肝素两天。她出院时服用达比加群四周。在这些病例（ITP和AF）中，抗凝治疗的选择并非简单直接，需要进一步研究。
Zotero 插件